

<https://doi.org/10.56770/jcp2025928>

A POTENTIAL IMPACT OF ARTIFICIAL INTELLIGENCE ON PHARMACEUTICAL DRUG DESIGN AND CLINICAL TRIALS

Muhammad Naeem Aamir^{1*}, Qurat Ul Ain², Sana Fatima³, Sabira Sultana⁴, Saleha Yasir⁵

¹Department of Pharmaceutics, The Islamia University of Bahawalpur, Punjab, Pakistan.

²School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China.

³Department of Microbiology and Molecular Genetics, The Women University Multan, Pakistan.

⁴Department of Eastern Medicine, Faculty of Medical Sciences, Government College University Faisalabad, Punjab, Pakistan.

⁵Center for Skill Development and Leadership, The University of Lahore, Pakistan.

Submitted: June 4, 2025; Revised: November 11, 2025; Accepted: November 19, 2025; Published: December 31, 2025

ABSTRACT

Pharmaceutical technology has increasingly integrated artificial intelligence (AI) in recent years. This technology offers significant benefits, including saving time and money while enhancing the understanding of the relationships between various formulation and process parameters. To address both specific and complex challenges, AI leverages human expertise and continually learns from the solutions it produces. Remarkable advances in processing power and AI capabilities could revolutionize drug development. However, the pharmaceutical industry currently faces challenges such as reduced efficiency and rising R&D costs, which hinder its ability to maintain medication development programs. Clinical trials, medication repurposing, drug discovery and development, and improved pharmaceutical production are just a few of the aspects of the pharmaceutical sector where artificial intelligence is increasingly being used. Additionally, by finding qualified individuals, forecasting treatment outcomes, and optimizing accuracy and speed, AI enhances the clinical trial process. AI makes precision treatment possible in personalized medicine by evaluating patient data and forecasting each patient's reaction to treatments.

Keywords: Artificial intelligence, Pharmacy, Drug design, Clinical trials.

*Corresponding Author. E-mail: naeem.aamir@iub.edu.pk

INTRODUCTION

Although the concept of artificial intelligence (AI) was first introduced around 1956, significant advancements have occurred in the last 12 to 15 years. Analyzing thousands of medical records and cases has become invaluable in delivering quicker treatments with excellent results. AI employs computer systems that emulate human intelligence to enhance human processes. The process involves data collection, formulating usage guidelines, drawing tentative or definitive conclusions, and rapidly self-correcting [1-3]. AI has a big impact on the pharmaceutical industry by improving smart production systems that help manufacturing, healthcare, and other industries. One significant aspect is the mobilization of processing capacity, which streamlines data administration and permits

access from any location. Sensitive and intelligent sensors lower costs, increase industrial productivity, and enhance machine communication [4, 5]. There is currently no widely recognized definition of artificial intelligence, despite its lengthy history. Nonetheless, the fundamental idea is to imitate human intelligence with computer systems. AI is essential to drug discovery, but the lack of cutting-edge technology makes the process difficult and time-consuming. AI is capable of quickly identifying hit and lead compounds, verifying drug targets, and improving the design of therapeutic structures.

In recent years, data digitalization in the pharmaceutical industry has surged, leading to the challenge of learning, analyzing, and utilizing this

Journal of Contemporary Pharmacy is published by AMMANIF. The authors retain the copyright without restriction. This article is an open access article published under the terms and conditions of [Creative Commons Attribution 4.0 International License](#).



information to solve complex medical issues. By leveraging sophisticated knowledge, artificial intelligence can address both specific and intricate problems. The integration of exceptional computational power with advancements in AI has the potential to revolutionize the drug development process [6].

The use of AI is encouraged due to its ability to manage vast amounts of data with enhanced automation. AI utilizes software and systems capable of analyzing and learning from input data to independently make decisions and complete specific tasks. However, it is essential to recognize certain research gaps. These include patient satisfaction with technology, long-term impacts such as effects on medical case reports, and ethical considerations like data privacy and potential biases. Additionally, technological challenges such as data integration, system maintenance, and usability for both patients and healthcare professionals must be addressed. By understanding these gaps, researchers can gain insights into the application of AI in the pharmaceutical and medical fields and develop solutions that maximize its benefits while ensuring ethical use and minimizing drawbacks [7-10].

ARTIFICIAL INTELLIGENCE CLASSIFICATIONS

AI is classified in two ways: According to quality and according to existence. According to quality, AI can be classified as follows:

Artificial Narrow Intelligence (ANI)

This system, sometimes referred to as weak AI, is made to carry out particular tasks including driving, chess, traffic signals, and facial recognition. It is engaged in tasks such as identifying appropriate patient groups for clinical trials, improving drug molecule architectures, predicting therapeutic efficacy, and evaluating big databases to find possible drug targets. Apple's own virtual assistant, Siri, is one example.

Artificial General Intelligence (AGI) or Strong AI

Referred to as human-level AI, AGI aims to replicate human intellectual abilities. It can solve unfamiliar tasks and has the potential to revolutionize drug discovery, development, and personalized medicine by analyzing extensive datasets to identify new drug targets, predict drug efficacy and toxicity, optimize clinical trials, and tailor treatment plans based on individual patients' unique genetic and medical histories. AGI can perform all tasks that humans can [11].

Artificial Super Intelligence (ASI)

This refers to cognitive abilities that surpass those of intelligent humans in areas such as space, mathematics, and creativity. ASI can range from computers that are slightly more intelligent than

humans to those that are trillions of times smarter across all subjects, from science to the arts.

According to existence, AI can be classified as follows:

Type 1

We refer to this kind of AI system as a "reactive machine." For instance, in the 1990s, IBM's chess program Deep Blue challenged chess champion Garry Kasparov. It can identify checkers on the chessboard and make predictions, but it lacks the memory to rely on prior experiences. It is useless in other situations because it was made for particular tasks. Google's AlphaGo is another illustration.

Type 2

A restricted memory system is the name given to this kind of AI system. It can handle present and future problems by drawing on prior experiences. Autonomous vehicles make decisions using this method. For example, recorded observations serve as the basis for future actions like changing lanes, even though these observations are not kept forever.

Type 3

The phrase "theory of mind" refers to this type of artificial intelligence system. It implies that each person has ideas, aspirations, and wants that affect their choices. But there isn't any AI of this kind yet.

Type 4

Self-awareness is the term for this kind. These artificial intelligence systems are sentient and self-aware. A machine that possesses self-awareness is able to comprehend its surroundings and apply ideas that come from other people's minds. But as of right now, this AI is nonexistent. The pharmaceutical industry is one of the many industries that use artificial intelligence nowadays [12-15].

ARTIFICIAL INTELLIGENCE IN DRUG DEVELOPMENT PROCESS

In the field of drug research, artificial intelligence (AI) is acknowledged as a revolutionary force. According to a new study, the healthcare system may be greatly impacted by big data and machine learning, which might lead to the creation of a \$100 billion yearly industry. According to industry analysts, medications created with AI techniques might not be available for two to three years, but they will eventually be crucial for the pharmaceutical business to compete. By analyzing massive datasets to find possible drug candidates, forecast chemical features, and improve drug design, artificial intelligence (AI) techniques like machine learning and deep learning can greatly speed up the drug development process.

This results in development that is quicker, more effective, and less expensive. Virtual screening, target selection, toxicity prediction, clinical trial optimization, and customized treatment based on

patient data analysis are important applications of AI.

Through early drug discovery, molecular design, target identification, clinical trial optimization, real-world data analysis, and customized medicine, artificial intelligence (AI) streamlines the drug development process.

In reality, a lot of what is referred to be artificial intelligence (AI) in the pharmaceutical sector is more akin to machine learning, which is an algorithmic process where computers provide better feedback. Without explicit programming, machines can learn from experience and improve their performance thanks to machine learning, a branch of artificial intelligence (AI) [16, 17].

Developing computer programs that can readily obtain data and learn on their own is its main objective. In particular, algorithms created to assess and forecast using novel and intricate features are referred to as machine learning. AI's predictive power may increase clinical trial success rates and speed up the drug development process, which would eventually result in the development of safer and more potent drugs. However, there are a number of issues that need to be resolved when using AI in drug discovery, one of which is the requirement for diverse and high-quality data.

Furthermore, obtaining regulatory approval and building trust in the scientific and medical communities depend on AI models being interpretable.

Artificial Intelligence in Pharmaceutical Nanotechnology: Certain AI techniques, such machine learning (ML), make it possible to analyze big data sets and identify intricate patterns. Therapeutics and diagnostics have advanced significantly in the field of nanomedicine. For example, medicinal molecules and imaging agents modified by nanoparticles have resulted in much better treatment outcomes and increased contrast efficiency.

Nanomedicine-based drug delivery is frequently investigated at set dosages, much like conventional combination therapy. However, a persistent problem with all drug administration techniques is the variability of pharmacological synergy caused by variables including time, dose, and unique patient conditions [18].

The development of nanomedicine-mediated co-delivery systems has made it possible to combine nanomedicine and artificial intelligence (AI) in order to optimize combinatorial nanotherapy. AI can successfully realize the full promise of nanomedicine in some areas, such as improving medication and dose parameters in combinatorial nanomedicine. Artificial intelligence and nanotechnology together offer creative answers to problems in the pharmaceutical and medical industries. sped clinical translation has been made

possible by the pharmaceutical industry's adoption of AI, which has reduced human labor and sped the attainment of desired results. Notable uses include improving and precisely forecasting material qualities and how they interact with biological systems, as well as developments in clinical trials, drug research, formulation design, and cancer diagnostics [19].

Nanomaterial design, image analysis, medication delivery optimization, non-manufacturing optimization, and toxicity prediction are some of the major uses of AI in nanotechnology. However, the incorporation of AI tools has been prompted by the intricacy, expense, and duration of laboratory procedures, as well as the enormous volumes of data produced and the difficulties in data analysis.

AI has been used to predict treatment efficacy and to design, characterize, and manufacture drug delivery nanosystems. It has been highlighted that it has the ability to forecast pharmacological qualities, optimize formulation design, and customize drug delivery depending on unique patient parameters. The creation of safe and efficient drug delivery systems can be expedited by utilizing AI and large datasets, which will ultimately improve patient outcomes and advance pharmaceutical sciences.

ARTIFICIAL INTELLIGENCE IN CLINICAL TRIALS

Developing new medications is an expensive and time-consuming process, often costing billions of dollars and taking ten years or more to reach the market. A significant risk is that organizations can face devastating consequences if drugs fail late-stage trials after generating considerable speculation. In this context, artificial intelligence (AI) is emerging as a crucial solution to these challenges and may be the key to successful drug development [20-22].

One of the most promising applications of AI in the pharmaceutical industry is its ability to rapidly analyze vast amounts of logical data, including research published in journals, medical records, tissue and blood tests, and study designs. This capability allows pharmaceutical companies to generate experimental hypotheses that facilitate the development of new drugs. Instead of employing a scattershot approach to screening potential compounds, companies can now create medications with greater precision by considering natural biomarkers. This enables organizations to focus on specific symptoms that a drug is particularly designed to treat.

For instance, tasks that would take a human researcher weeks or even months to complete can be accomplished in just minutes by IBM's AI supercomputer, Watson. Through machine learning, Watson and similar systems continuously improve and accelerate their processes by updating

algorithms to incorporate new findings. Ultimately, this rapid screening could allow for the analysis of the entire genome of a patient's cancer, enabling the customization of medications based on individual mutations. If a suitable treatment is not available, organizations are poised to pursue that opportunity [23].

AI innovations have made significant strides, leading an increasing number of businesses to leverage these advancements to tackle complex challenges and explore new frontiers. Despite some perceptions of artificial intelligence as outdated or a realm of science fiction, there are tangible applications that can help organizations manage vast data sets, enhance human decision-making, and provide expert insights to clients.

Artificial intelligence (AI) has made tremendous strides, and an increasing number of companies are focusing on using these advancements to both break new ground and solve commercial challenges. Although many may consider computerized reasoning to be a thing of the past and the domain of science fiction, there are practical applications that can assist organizations with complex problems, such as understanding massive amounts of data, improving human decision-making, or offering clients expert advice [24-26].

The time for AI advancements is now. This surge is driven by significant increases in registration and the availability of computing power at affordable prices, enabling complex computations to be completed in seconds instead of weeks. According to Forrester, "artificial intelligence" encompasses the theories and skills aimed at replicating human

knowledge through learning and experience. AI capabilities incorporate complex thinking models to tackle intricate problems and provide innovative solutions. Engineers are increasingly leveraging AI in the business sector to develop subjective computing systems. This decade marks a rapid progression in artificial intelligence (AI), which Forrester predicts will become integral to daily interactions with computers, devices, wearables, and systems. This technology will assist users in completing tasks, finding answers, making decisions, and automating repetitive tasks. Ultimately, AI is expected to drive business growth by helping organizations better serve their clients, which will significantly enhance its adoption in the enterprise space. AI advancements are accessible across various markets and sectors, offering five key business capabilities [27-30].

Artificial Intelligence in Pharmaceutical Manufacturing

The technologies used in pharmaceutical manufacturing are evolving as traditional methods, procedures, and business models face challenges from the Internet of Things, artificial intelligence (AI), robotics, and advanced computing. Pharmaceutical manufacturing might become considerably more flexible, efficient, agile, and high-quality with the integration of these technologies. A significant turning point in the development of the pharmaceutical sector has been reached with the confluence of AI and manufacturing, which offers previously unheard-of chances to improve decision-making and quality control.




Figure 1: Comparison of AI and traditional pharmaceutical manufacturing.

The production of pharmaceutical drugs is a complex process that spans from formulation development to the final product. During this process, raw ingredients and processing conditions interact in various ways, significantly influencing the quality and processability of the final product. In recent years, artificial intelligence (AI) has gained traction in pharmaceutical technology, offering the potential to save time and reduce costs while enhancing our understanding of the relationships between different formulation and process characteristics. Emerging technologies such as fuzzy logic, neural networks, and genetic algorithms show promise in pharmaceutical production and processing. Fuzzy logic serves as an effective problem-solving tool for control and decision-making, generating useful rules in the format of "if... then." Neuro-fuzzy logic, which combines fuzzy logic with neural networks, enhances adaptability and capability, leading to powerful outcomes.

AI improves a number of pharmaceutical manufacturing processes, such as production scheduling, process monitoring, quality control, and predictive maintenance. AI finds trends, anticipates possible problems, and permits real-time modifications by examining massive information from manufacturing equipment. In the end, this increases productivity, cuts waste, and guarantees product quality while adhering to strict legal requirements. AI transforms decision-making through its analytical capabilities and protects product integrity by strictly adhering to quality standards. AI gives stakeholders useful insights that guide resource allocation and strategic planning by sorting through complicated datasets [31].

AI in Drug Design

Finding and verifying therapeutic targets, producing hits and leads, optimizing leads, finding preclinical candidates, carrying out preclinical research, and overseeing clinical studies are all steps in the process. Since the development of computational chemistry in the late 1980s and early 1990s, interest in artificial intelligence for drug creation has increased dramatically. We are offered quick and broad solutions to drug design problems as we work to create novel medicines, frequently ignoring lessons learned from the past [32-34].

Artificial intelligence (AI) plays a significant role in our daily lives, achieving notable breakthroughs in various fields such as speech and image recognition, and natural language processing. Its power in Quantitative Structure-Property Relationships (QSPR) and Quantitative Structure-Activity Relationships (QSAR) is evident through a growing number of applications in predicting

properties and activities, including physicochemical and ADMET characteristics [35]. AI is now a potent data mining tool in drug creation thanks to the development of machine learning theory and the collection of pharmacological data. Virtual screening, activity scoring, QSAR analysis, de novo drug creation, and in-silico assessment of absorption, distribution, metabolism, excretion, and toxicity (ADME/T) features are just a few of the fields in which it is crucial. AI-powered de novo design makes it easier to create new physiologically active substances with desired properties, demonstrating the power of AI through a number of case studies. In the near future, it is expected that the combination of planning and ease of synthesis would improve computer-assisted drug development.

CONCLUSION

Although there aren't any drugs using AI techniques on the market yet, one is anticipated to be created in the next two to three years. Experts are adamant that AI will eventually revolutionize medication research and the pharmaceutical industry. Even though AI might speed up the creation of new medications, more research is necessary. AI can also be a useful tool in the medical field, assisting with gene therapy and other treatments that are not yet accessible to humans. The phrase "computational intelligence" refers to a broad range of approaches, including statistical and machine learning, logic, probability theory, pattern recognition, and biologically inspired techniques like neural networks, evolutionary computing, and fuzzy modeling. Drug compounds and peptides are being rationally designed using a variety of AI components, including artificial neural networks (ANN), deep learning, machine learning, and genetic programming. By anticipating negative outcomes in clinical studies and gathering patient data, AI has also had a major impact on healthcare. This makes it possible to provide test data and results right away, which helps patients choose the best course of treatment. AI has the potential to propel the creation of cutting-edge software and technology in the future, improving health management plans and the creation of pharmaceutical products.

Author(s) Contribution: Conceptualization, M. A. Naeem; analysis, Qurat ul Ain; editing, F. Sana; proof-reading, S. Sabira; data collection, Y. Saleha.

Funding: Nill

Ethical Approval: NA

Conflict of Interest: There is no conflict of interest.

Consent for Publication: All authors approved the manuscript for publication and agreed to be responsible for all aspects of this article.

REFERENCES

1. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratana T, Suwanpitak K and Sangnim T: The artificial intelligence-driven pharmaceutical industry: a paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post- market surveillance. *European Journal of Pharmaceutical Sciences* 2024; 16: 106938.<https://doi.org/10.1016/j.ejps.2024.106938>
2. Sultana A, Maseera R, Rahamanulla A and Misiriya A: Emerging of artificial intelligence and technology in pharmaceuticals. *Future Journal of Pharmaceutical Sciences* 2023; 9(1): 65. <https://doi.org/10.1186/s43094-023-00517-w>
3. Haleem A, Javaid M and Khan IH: Current status and applications of Artificial Intelligence (AI) in medical field: An overview. *Current Medicine Research and Practice* 2019; 9(6): 231-237.<https://doi.org/10.1016/j.cmrp.2019.11.005>
4. Mak, K.-K. and Pichika M.R., Artificial intelligence in drug development: present status and future prospects. *Drug discovery today*, 2019. 24(3): p. 773-780. <https://doi.org/10.1016/j.drudis.2018.11.014>
5. Russell, S., Dewey D., and Tegmark M., Research priorities for robust and beneficial artificial intelligence: an open letter. *AI Magazine*, 2015. 36(4). <https://doi.org/10.1609/aimag.v36i4.2577>
6. Shakya, S., Analysis of artificial intelligence based image classification techniques. *Journal of Innovative Image Processing (JIIP)*, 2020. 2(01): p. 44-54. <https://doi.org/10.36548/jiip.2020.1.005>
7. Kulkov I: The role of artificial intelligence in business transformation: A case of pharmaceutical companies. *Technology in Society* 2021; 66: 101629. <https://doi.org/10.1016/j.techsoc.2021.101629>
8. Arden NS, Fisher AC, Tyner K, Lawrence XY, Lee SL and Kopcha M: Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International Journal of Pharmaceutics* 2021; 602: 120554.<https://doi.org/10.1016/j.ijpharm.2021.120554>
9. Javaid M and Haleem A: Industry 4.0 applications in medical field: A brief review. *Current Medicine Research and Practice* 2019; 9(3): 102-109. <https://doi.org/10.1016/j.cmrp.2019.04.001>
10. Yildirim, O., et al. , Opportunities and challenges for drug development: public–private partnerships, adaptive designs and big data. *Frontiers in pharmacology*, 2016. 7: p. 461. <https://doi.org/10.3389/fphar.2016.00461>
11. Medarević, D.P., et al. , Combined application of mixture experimental design and artificial neural networks in the solid dispersion development. *Drug development and industrial pharmacy*, 2016. 42(3): p. 389-402. <https://doi.org/10.3109/03639045.2015.1054831>
12. Barmapalexis P, Koutsidis I, Karavas E, Louka D, Papadimitriou SA, Bikiaris DN. Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique and optimization of dissolution using artificial neural networks. *European Journal of Pharmaceutics and Biopharmaceutics*. 2013 Nov 1;85(3):1219-31. <https://doi.org/10.1016/j.ejpb.2013.03.013>
13. Damiani SA: Digital pharmaceutical sciences. *AAPS Pharmaceutical Science & Technology* 2020; 21(6): 206. doi: 10.1208/s12249-020-01747-4
14. Vobugari N, Raja V, Sethi U, Gandhi K, Raja K and Surani SR: Advancements in oncology with artificial intelligence a review article. *Cancers* 2022; 14(5): 1349.doi: <https://doi.org/10.3390/cancers14051349>
15. Khan O, Parvez M, Kumari P, Parvez S and Ahmad S: The future of pharmacy: how AI is revolutionizing the industry. *Intelligent Pharmacy* 2023; 1(1): 32-40.doi: <https://doi.org/10.1016/j.ipha.2023.04.008>
16. Xin Y, Man W and Yi Z: The development trend of artificial intelligence in medical: A patentometric analysis. *Artificial Intelligence in the Life Sciences* 2021; 1: 100006. <https://doi.org/10.1016/j.ailsci.2021.100006>
17. Raza MA, Aziz S, Noreen M, Saeed A, Anjum I, Ahmed M and Raza SM: Artificial intelligence (AI) in pharmacy: an overview of innovations. *Innovations in Pharmacy* 2022; 13(2). Doi: [10.24926/iip.v13i2.4839](https://doi.org/10.24926/iip.v13i2.4839)

18. Lamberti MJ, Wilkinson M, Donzanti BA, Wohlhieter GE, Parikh S, Wilkins RG and Getz K: A study on the application and use of artificial intelligence to support drug development. *Clinical Therapeutics* 2019; 41(8): 1414-1426.
<https://doi.org/10.1016/j.clinthera.2019.05.018>
19. Colombo S: Applications of artificial intelligence in drug delivery and pharmaceutical development. In *Artificial intelligence in healthcare* 2020; 85-116.
<https://doi.org/10.1016/B978-0-12-818438-7.00004-6>
20. King MR: The future of AI in medicine: a perspective from a Chatbot. *Annals of Biomedical Engineering* 2023; 51(2): 291-295.
doi: <https://doi.org/10.1007/s10439-022-03121-w>
21. Mirmozaffari M, Yazdani R, Shadkam E, Khalili SM, Mahjoob M and Boskabadi A: An integrated artificial intelligence model for efficiency assessment in pharmaceutical companies during the COVID-19 pandemic. *Sustainable Operations and Computers* 2022; 3: 156-167.
<https://doi.org/10.1016/j.susoc.2022.01.003>
22. Gampala S, Vankeshwaram V and Gadula SS: Is artificial intelligence the new Friend for radiologists? A review article. *Cureus* 2020; 12(10): 11137.doi: 10.7759/cureus.11137
23. Beam AL, Drazen JM, Kohane IS, Leong TY, Manrai AK and Rubin EJ: Artificial intelligence in medicine. *New England Journal of Medicine* 2023; 388(13): 1220-1221.doi: 10.1056/NEJMe2206291
24. Jiménez-Luna J, Grisoni F, Weskamp N and Schneider G: Artificial intelligence in drug discovery: recent advances and future perspectives. *Expert Opinion on Drug Discovery* 2021; 16(9): 949-959.
<https://doi.org/10.1080/17460441.2021.1909567>
25. Moore JA and Chow JC: Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modelling. *Nano Express* 2021; 2(2): 022001.doi: <https://doi.org/10.1093/bib/bbab523>
26. Arden NS, Fisher AC, Tyner K, Lawrence XY, Lee SL and Kopcha M: Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *Intern J of Pharmaceutics* 2021; 602: 120554.doi: <https://doi.org/10.1016/j.ijpharm.2021.120554>
27. Arabi AA: Artificial intelligence in drug design: algorithms, applications, challenges and ethics. *Future Drug Discovery* 2021; 3(2): 59.
28. Luukkonen S, van den Maagdenberg HW, Emmerich MT and van Westen GJ: Artificial intelligence in multi- objective drug design. *COSB* 2023; 79: 102537.
29. Arend Hintze. Understanding the four types of AI. [cited 2022. 13 June]; Available from: <https://theconversation.com/understanding-the-four-types-of-ai-from-reactive-robots-to-self-aware-beings-67616>.
30. Ganapathy K, Abdul SS, Nursetyo AA. Artificial intelligence in neurosciences: A clinician's perspective. *Neurology India*. 2018 Jul 1;66(4):934-9. 10.4103/0028-3886.236971
31. Manikiran SS, Prasanthi NL. Artificial intelligence: milestones and role in pharma and healthcare sector. *Pharma times*. 2019;51:9-56.
32. Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT. Computational approaches in target identification and drug discovery. *Computational and structural biotechnology journal*. 2016 Jan 1;14:177-84.doi: <https://doi.org/10.1016/j.csbj.2016.04.004>
33. Ho D, Wang P and Kee T: Artificial intelligence in nanomedicine. *Nanoscale Horizons* 2019; 4(2): 365-377.doi: [10.1039/C8NH00233A](https://doi.org/10.1039/C8NH00233A)
34. Saeed H, El Naqa I. Artificial intelligence in clinical trials. In *Machine and deep learning in oncology, medical physics and radiology* 2022 Feb 2 (pp. 453-501). Cham: Springer International Publishing. 10.1007/978-3-030-83047-2_19
35. Shao D, Dai Y, Li N, Cao X, Zhao W, Cheng L, Rong Z, Huang L, Wang Y and Zhao J: Artificial intelligence in clinical research of cancers. *Briefings in Bioinformatics* 2022; 23(1): 523.
<https://doi.org/10.1093/bib/bbab523>